Supplemental Table of Contents

Table S1: Vaccine Effectiveness for testing positive for COVID -19 (COVID-19 Tests Results from 01 Jan 21 – 19 October 21); Adult KRT Population as of 19 September 2021

Table S2: Vaccine Effectiveness for Hospitalization within 14 days of positive test COVID-19 Tests Results from 01 Mar 21 - 05 October 21

Table S3: Vaccine Effectiveness (Transplant patients only) for testing positive for COVID -19 (COVID-19 Tests Results from 01 Jan 21 – 19 October 21); Adult KRT Population as of 19 September 2021

Table S4: Vaccine Effectiveness (Transplant patients only) for hospitalization within 14 days of positive test COVID-19 Tests Results from 01 Mar 21 - 05 October 21

Figure S1a Monthly number of positive SARS-CoV-2 patients on dialysis in Scotland split by status at day 28 (alive in dark blue/dead in purple)

Figure S1b: Monthly number of positive SARS-CoV-2 patients with a kidney transplant in Scotland split by status at day 28 (alive in dark blue/dead in purple)

Figure S2a: Kaplan-Meier curve of 28-day survival following a positive SARS-CoV-2 PCR test in patients on dialysis in Scotland split by wave.

Figure S2b: Kaplan-Meier curve of 28-day survival following a positive SARS-CoV-2 PCR test in patients with a functioning kidney transplant in Scotland, split by wave.

Figures S3a and b: Bootstrap distribution with 95% confidence interval for relative risk of hospitalization (a) and testing positive (b) in vaccinated versus unvaccinated individuals.




Figure S1a Monthly number of positive SARS-CoV-2 patients on dialysis in Scotland split by status at day 28 (alive in dark blue/dead in purple)




Figure S1b: Monthly number of positive SARS-CoV-2 patients with a kidney transplant in Scotland split by status at day 28 (alive in dark blue/dead in purple)

Table S1: Vaccine Effectiveness for testing positive for COVID -19 (COVID-19 Tests Results from 01 Jan 21 – 19 October 21); Adult KRT Population as of 19 September 2021

| | Positive SARS-CoV-2 | | | |
|------------------------------------|---------------------|-------|-----------|--|
| | Yes | No | All Cases | |
| Vaccinated | 357 | 4654 | 5011 | |
| Non-Vaccinated | 25 | 210 | 235 | |
| All | 382 | 4864 | 5246 | |
| | Risk of SARS-CoV-2 | | | |
| Vaccinated | | 0.07 | | |
| Non-Vaccinated | 0.11 | | | |
| Risk of COVID-19 in Vaccinated | | 7% | | |
| Risk of COVID-19 in Non-Vaccinated | | 11% | | |
| Risk Ratio | | 0.67 | | |
| Vaccine Effectiveness | 33% 95% CI ((| 0-52) | | |
| | | | | |
| | | | | |

Table S2: Vaccine Effectiveness for Hospitalization within 14 days of positive test COVID-19 Tests Results from 01 Mar 21 - 05 October 21

| | Hospitalisation | | | |
|---|-------------------------|----------|---------------------------|--|
| | Yes | No | All Positive Cases | |
| Vaccinated | 110 | 216 | 326 | |
| Non-Vaccinated | 12 | 10 | 22 | |
| All | 122 | 226 | 348 | |
| | Risk of Hospitalisation | | | |
| Vaccinated | 0.34 | | | |
| Non-Vaccinated | 0.55 | | | |
| Risk of Hospitalisation in Vaccinated | | 34% | | |
| Risk of Hospitalisation in Non-Vaccinated | 55% | | | |
| Risk Ratio | | 0.62 | | |
| Vaccine Effectiveness | 38% (95% C | 1 0- 57) | | |

Table S3: Vaccine Effectiveness (Transplant patients only) for testing positive for COVID -19 (COVID-19 Tests Results from 01 Jan 21 – 19 October 21); Adult KRT Population as of 19 September 2021

| | Positive SARS-CoV-2 | | | |
|--|---------------------|------|-------|--|
| | Yes | No | Total | |
| Vaccinated | 259 | 2860 | 3119 | |
| Non-Vaccinated | 22 | 139 | 161 | |
| All | 281 | 2999 | 3280 | |
| | Risk of Infection | | | |
| Vaccinated | 0.08 | | | |
| Non-Vaccinated | 0.14 | | | |
| Risk of Hospitalisation in Vaccinated Risk of Hospitalisation in Non- Vaccinated | 8% | | | |
| | 14% | | | |
| Risk Ratio | 0.61 | | | |
| Vaccine Effectiveness | 39% | | | |
| | | | | |

Table S4: Vaccine Effectiveness (Transplant patients only) for hospitalization within 14 days of positive test COVID-19 Tests Results from 01 Mar 21 - 05 October 21

| | Hospitalisation | | | |
|---|-----------------------|-------|-------|-----|
| | Yes | No | Total | |
| Vaccinated | 81 | 154 | | 235 |
| Non-Vaccinated | 11 | 8 | | 19 |
| All | 92 | 162 | | 254 |
| | Risk of Hospitalis | ation | | |
| Vaccinated | 0.34 | | | |
| Non-Vaccinated | 0.58 | | | |
| Risk of Hospitalisation in Vaccinated | 34% | | | |
| Risk of Hospitalisation in Non-Vaccinated | 58% | | | |
| Risk Ratio | 0.60 | | | |
| Vaccine Effectiveness | 40% | | | |




Figure S2a: Kaplan-Meier curve of 28-day survival following a positive SARS-CoV-2 PCR test in patients on dialysis in Scotland split by wave.





Figure S2b: Kaplan-Meier curve of 28-day survival following a positive SARS-CoV-2 PCR test in patients with a functioning kidney transplant in Scotland, split by wave.



Figures S3a and b: Bootstrap distribution with 95% confidence interval for relative risk of hospitalization (a) and testing positive (b) in vaccinated versus unvaccinated individuals.